All In Biotech

Drug Trial Radar · NCT05798611

Study of ART0380 in Patients With Biologically Selected Solid Tumors

A Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients With Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

36

Actual

Start

Sep 6, 2023

Primary completion

Nov 15, 2024

Study completion May 27, 2025

Sponsor

Lead sponsor
Artios Pharma LtdIndustry
Sponsor type
Industry
First posted
Apr 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).

Conditions

  • Advanced Solid Tumor
  • Recurrent Endometrial Cancer
  • Metastatic Cancer

Interventions

  • ART0380Drug

    Randomized patients will orally receive ART0380.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Until disease progression (Every 6 weeks from randomization Upto 2 Years)

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles (UCLA)

    Los Angeles, California

  • The University of Chicago

    Chicago, Illinois

  • Dana Farber Cancer Center

    Boston, Massachusetts

  • Northwell Health R.J. Zuckerberg Cancer Center

    Lake Success, New York

  • Memorial Sloan Kettering Cancer Center (MSKCC) - Memorial Hospital - Oncology

    New York, New York

  • University of Oklahoma/Sarah Cannon Research Institute

    Oklahoma City, Oklahoma

  • Western Pennsylvania Hospital

    Pittsburgh, Pennsylvania

  • Women and Infants Hospital

    Providence, Rhode Island

  • Institut de Cancérologie de l'Ouest

    Angers, NAP, France

  • Centre Francois Baclesse - Service d'Oncologie médicale

    Caen, NAP, France

  • Hopital Cochin Saint Vincent De Paul

    Paris, NAP, France

  • Hopital Lyon Sud

    Pierre-Bénite, NAP, France

  • Centre Hospitalier Universitaire De Poitiers

    Poitiers, NAP, France

  • Fundación Instituto Valenciano De Oncología

    Valencia, Spain

  • Hospital Universitario De Jaén

    Jaén, Andalusia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.